Perrigo Company plc Other Restructuring Costs
Perrigo Company plc (PRGO) reported Other Restructuring Costs of $54.50 million for the 9-month period ending 2025-09-27, per its 10-Q filed 2025-11-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherRestructuringCosts · last filed 2025-11-05
- Perrigo Company plc other restructuring costs for the quarter ending 2025-09-27 was $19.50M, a 306.25% increase year-over-year.
- Perrigo Company plc other restructuring costs for the quarter ending 2024-09-28 was $4.80M, a 108.70% increase year-over-year.
- Perrigo Company plc other restructuring costs for the quarter ending 2023-09-30 was $2.30M.
| Period end | Other Restructuring Costs 3 month | Other Restructuring Costs 6 month | Other Restructuring Costs 9 month |
|---|---|---|---|
| 2025-09-27 | $19.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $54.50M 10-Q · filed 2025-11-05 | |
| 2025-06-28 | $35.00M 10-Q · filed 2025-08-06 | ||
| 2024-09-28 | $4.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $43.10M 10-Q · filed 2025-11-05 | |
| 2024-06-29 | $38.30M 10-Q · filed 2025-08-06 | ||
| 2023-09-30 | $2.30M 10-Q · filed 2023-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |